Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder

Mani N. Pavuluri, David B. Henry, Robert L. Findling, Stephanie Parnes, Julie A. Carbray, Tahseen Mohammed, Philip G. Janicak, John A. Sweeney

Research output: Contribution to journalArticlepeer-review

63 Scopus citations


Objective: To determine the relative effects of risperidone and divalproex in pediatric mania. Methods: This is a double-blind, randomized, outpatient clinical trial with 66 children and adolescents (mean age = 10.9 ± 3.3 years; age range = 8-18 years) with mania who were randomly assigned to either risperidone (0.5-2 mg/day, n = 33) or divalproex (60-120 μg/mL, n = 33) for a six-week period. Measures included the Young Mania Rating Scale (YMRS) and Child Depression Rating Scale-Revised (CDRS-R). Results: Mixed-effects regression models, with interaction between time and the active drug as predictors, found that the risperidone group had more rapid improvement than the divalproex group (p < 0.05), although final scores did not differ significantly between groups. Mixed models using only those subjects who completed the six-week study found similar results. The response rate on YMRS was 78.1% for risperidone and 45.5% for divalproex (p < 0.01). The remission rate for risperidone was 62.5%, compared with 33.3% for divalproex (p < 0.05). Improvement on the CDRS-R was significantly higher for the risperidone group relative to the divalproex group (p < 0.05). There were no significant differences between groups in safety, but subject retention was significantly higher at study endpoint in the risperidone group (p < 0.01). Dropout rate was 24% in the risperidone group and 48% in the divalproex group, with increased irritability being the most common reason for dropout in the latter. There was no significant weight gain in either group. Conclusion: Results suggest that risperidone was associated with more rapid improvement and greater reduction in manic symptoms compared to divalproex. Although the results suggest that both drugs are safe, risperidone's lower attrition rate and lower rate of adverse events may suggest better toleration. Clinical trials with larger samples are required to confirm these preliminary findings.

Original languageEnglish (US)
Pages (from-to)593-605
Number of pages13
JournalBipolar Disorders
Issue number6
StatePublished - Oct 2010


  • Bipolar disorder
  • Divalproex
  • Double blind
  • Mania
  • Randomized
  • Risperidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder'. Together they form a unique fingerprint.

Cite this